Кореспондиращ автор: Ц. Бонева ( dr.boneva@abv.bg ) Академик редактор: Yoto Yotov © Ц. Бонева, Р. Иванова, Г. Златанчева, Д. Василев, К. Карамфилов. Това е статия отворен достъп разпространява под условията на Creative Commons Attribution License (CC BY 4.0), която позволява използване без ограничения, разпространение, и възпроизвеждане на всякакъв носител, при условие на оригиналния автор и източник са кредитирани. Цитат:
Бонева Ц, Иванова Р, Златанчева Г, Василев Д, Карамфилов К (2022) Серумни биомаркери за пулмонална хипертония. Българска Кардиология 28(2): 59-68. https://doi.org/10.3897/bgcardio.28.e79181 |
Corresponding author: Ts. Boneva ( dr.boneva@abv.bg ) Academic editor: Yoto Yotov © Ts. Boneva, R. Ivanova, G. Zlatantcheva, D. Vasilev, K. Karamfiloff. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Citation:
Boneva T, Ivanova R, Zlatantcheva G, Vasilev D, Karamfiloff K (2022) Serum biomarkers for pulmonary hypertension. Bulgarian Cardiology 28(2): 59-68. https://doi.org/10.3897/bgcardio.28.e79181 |
In the fi eld of development of pathophysiology of pulmonary hypertension, there are growing number of signifi cant recent advances, which leads to new therapeutic agents. Traditional methods of diagnosing and monitoring this condition have comprised echocardiography and right heart catheterization, in addition to functional measures, such as estimation of functional class and the 6-min walk test. An increasing number of biomarkers have been described that are elevated in pulmonary hypertension and which may assist the clinician in diagnosis and in the assessment of disease severity and response to treatment.